Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-16-Speech-3-199-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-02-16"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"lt"^^xsd:language2
lpv:document identification number	"en.20110216.11.3-199-000"2
lpv:hasSubsequent	lp_eu:2011-02-16-Speech-3-200-0002
lpv:speaker	lp:Vilija Blinkevičiūtė2
lpv:spokenAs	substitute; EMPL (2009-07-16--2012-01-18)3,3 substitute; FEMM (2009-07-16--2012-01-18)3,3 member; LIBE (2009-07-16--2012-01-18)3,3 member; S&D (2009-07-14--2014-06-30)3,3 vice-chair; Delegation to the EU-Ukraine Parliamentary Cooperation Committee (2009-09-29--2014-06-30)3,3 member; Delegation to the Euronest Parliamentary Assembly (2009-10-07--2014-06-30)3,3 unknown; Lietuvos socialdemokratų partija (2009-07-14--2014-06-30)3,3 substitute; Delegation to the EU-Kazakhstan, EU-Kyrgyzstan and EU-Uzbekistan Parliamentary Cooperation Committees, and for relations with Tajikistan, Turkmenistan and Mongolia (2009-09-16--2014-06-30)3,3
lpv:translated text	"I voted in favour of this report because we must take into account a concern which is getting higher and higher on the agenda of the European citizens: the quality and safety of the medicinal products they are consuming. There is data indicating a sharp increase in seizures of falsified medicines by customs. For instance, 2.7 million medicinal products were confiscated at EU custom borders in 2006 and 2.5 million in 2007, hence seizures of medicines are up 384% compared to 2005. The report observes a trend from the falsification of ‘lifestyle’ medicines to life-saving medicines, including medicines to treat cancer and heart disease, psychiatric disorders and infections. Treatment with such falsified medicines can have fatal consequences. Furthermore, there is a trend towards targeting the classical supply chain. Besides the Internet, the licensed distribution chain is increasingly targeted. Out of the 13 Member States that had data, seven reported incidences of counterfeit medicinal products in the legal supply chain. Patients need to be absolutely sure that the medicines they consume really are the medicines they expect them to be. The use of falsified medicines can result in therapeutic failure and can put lives at risk. I therefore believe that the protection of public health against falsified medicines should be the main focus of the directive. This focus should not be troubled by other additional objectives."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph